News

Contract Development and Manufacturing Organizations (CDMOs), which pharmaceutical companies increasingly delegate product development and manufacturing, operate in a fragmented market undergoing substantial consolidation. Yet, many CDMOs fail to fully capitalize on pricing projects, risking competitiveness. To thrive, they must...

According to insights, the pharmaceutical CDMO market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.29% until 2028. This growth could be attributed to the expanding pharmaceutical sector, driven by the increasing usage of analytics...

The projected worth of the Global Small Molecule Innovator CDMO Market is anticipated to surpass $76.50 billion by 2031, displaying a compounded annual growth rate (CAGR) of 6.1% during the estimated timeframe. Contract Development and Manufacturing Organizations (CDMOs) offer...

Parexel, a CRO providing a full range of Phase I to IV clinical development services, and Partex, a digital pharma platform, entered a strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for...

AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to...

Chiesi Global Rare Diseases has entered a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier (BBB)-crossing platform technology to address challenging disease areas with high unmet need.The collaboration will focus on multiple enzyme cargoes...

Croda Pharma has introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need for replacing the popular, but now banned,...